Prosecution Insights
Last updated: November 15, 2026
Application No. 17/335,251

METHODS AND MATERIALS FOR ACTIVATING AN INTERNAL RIBOSOME ENTRY SITE IN EXON 5 OF THE DMD GENE

Final Rejection §112§DOUBLEPATENT
Filed
Jun 01, 2021
Priority
Aug 09, 2014 — provisional 62/035,395 +3 more
Examiner
MCLEOD, AFRICA MHAIRIE
Art Unit
1635
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
University Of Western Australia
OA Round
2 (Final)
55%
Grant Probability
Moderate
3-4
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 55% of resolved cases
55%
Career Allowance Rate
31 granted / 56 resolved
-4.6% vs TC avg
Strong +64% interview lift
Without
With
+63.8%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
34 currently pending
Career history
105
Total Applications
across all art units

Office Action

§112 §DOUBLEPATENT
DETAILED ACTION A preliminary amendment was received and entered on 6/1/2021. Claims 1-23 were canceled and claims 24-39 were added. Claims 24-39 are pending and under consideration. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 24-39 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for a method of increasing expression of functional dystrophin in a DMD or BMD patient with a 5' mutation in a DMD gene, but without a DMD exon 2 duplication, by administration of a recombinant AAV vector comprising a U7snRNA expression construct capable of expressing a fusion of U7 snRNA and instant SEQ ID NO: 10, does not reasonably provide enablement for methods of increasing dystrophin expression in a DMD or BMD patient by administering an AAV vector expressing SEQ ID NO: 9, 11, and/or 12, but not SEQ ID NO: 10. The claims are drawn to methods of ameliorating DMD or BMD in a patient with a 5' mutation in a DMD gene, but who does not have a DMD exon 2 duplication, by administering to the patient a recombinant adeno-associated virus (rAAV) comprising a DMD exon 5 internal ribosome entry site (IRES)-activating oligomer construct that induces skipping of exon 2 and activates the DMD exon 5 IRES comprising any one or more of the nucleotide sequences set forth in SEQ ID NOS: 5, 7 or 8 or encoding one of SEQ ID NOS: 9, 11 or 12 (which correspond to SEQ ID NOS: 5, 7, and 8, respectively). The specification also discloses at [0075] that an individual with a naturally-occurring deletion of exon 2 (which leads to a premature stop codon) had no reported muscular dystrophy, and that the individual produced an N-terminally truncated dystrophin. The inventors performed tandem mass spectrometry on peptides derived from the individual's dystrophin protein, and detected 99 unique dystrophin peptides, none of which was from exons 1-6. This is consistent with translation initiation downstream of the exon 5 IRES. These results provide evidence consistent with the idea that deletion or skipping of exon 2 can result in stimulation of the IRES in exon 5. This forms the foundation of the invention as claimed, which is directed toward addressing 5' DMD mutations (defined at specification page 20, paragraph 48 as mutations in DMD exons 1-4) by activating the exon 5 IRES to stimulate translation beginning in exon 6. Therefore enablement of the claimed invention is considered to depend on the ability of the recited AAV vectors to induce skipping of exon 2 in patients that lack an exon 2 duplication. The specification discloses at page 34 that separate U7snRNA constructs comprising sequences B, C, AL, and AS, (encoding SEQ ID NOS: 9-12, respectively) were cloned into AAV vectors to assess their ability to induce skipping of exon 2 in myoblasts generated from fibroblast cell lines that express either wild type DMD or DMD with a duplication of exon 2. The specification indicates that all constructs were able to skip either one or two copies of exon 2, referring to Fig. 10. The resolution of Fig. 10 is poor and it is unclear that any construct other than U7-C (which expresses instant SEQ ID NO: 10) induces exon skipping in wild type DMD mRNA having only one copy of exon 2. Wein et al (Nature Medicine 20(9): 992-1000, 2014, of record) appears to disclose the same data as instant Fig. 10 in Supplementary Fig. 4. Wein indicates that while U7-C is able to induce exon-skipping in both wild type mRNA and mRNA with a duplicated exon 2, U7-AL (expressing instant SEQ ID NO: 11) is only able to induce skipping in mRNA with a duplicated exon 2. The results for constructs expressing B or AS (SEQ ID NOS: 9 and 12, respectively) do not appear to show skipping of exon 2 in the context of a DMD mRNA lacking an exon 2 duplication. Please note that the claims exclude subjects with duplications in exon 2. It appears from the evidence in Fig. 10 that rAAV vectors expressing only one or more copies of SEQ IDS NOS: 9, 11, or 12 (but no copy of SEQ IDNO: 10) do not induce skipping of exon 2 in the context of an RNA that does not have a duplication of exon 2. Because the evidence of record indicates that recombinant AAV constructs designed to express only SEQ ID NOS: 9, 11, or 12 do not induce skipping of exon 2 in a DMD mRNA lacking a duplication of exon 2, and because it appears that skipping of exon 2 is required in order to achieve activation of the exon 5 IRES and subsequent production of an active dystrophin protein, one of skill in the art could not practice the invention commensurate in scope with the claims without undue experimentation. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 24-39 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-27 of U.S. Patent No. 11053494. Although the claims at issue are not identical, they are not patentably distinct from each other The ‘494 patent claims methods of ameliorating DMD or BMD in a patient with a 5’ mutation in a DMD gene but without a DMD exon 2 duplication, the method comprising the step of administering to the patient a rAAV comprising a DMD exon 5 IRES-activating oligomer construct comprising the nucleotide sequence set forth in instant SEQ ID NO: 6 or a nucleotide sequence that expresses an RNA transcript comprising the nucleotide sequence set forth in instant SEQ ID NO: 10. See claim 1. ‘494 claims 9, 11, and 12 depend from claim 1 and indicate that the construct also comprises the sequence set forth in instant SEQ ID NO: 5, 7, or 8, respectively, and ‘494 claims 13, 15 and 16 depend from claim 1 and indicate that the construct can express an RNA transcript comprising the nucleotide sequence of instant SEQ ID NOS 9, 11, or 12, respectively. ‘494 claims 18-20 depend from claim 1 and also provide for such methods where the IRES-activating oligomer construct comprises instant SEQ ID NO: 7, and claims 22-25 depend from claim 1 and provide for such methods wherein the construct expresses an RNA comprising instant SEQ ID NO: 11. Thus the ‘494 claims anticipate instant claims 24 and 33-38. ‘494 claims 2-8 provide for the limitations of instant claims 25-32. ‘494 claim 27 further requires administering a glucocorticoid to the patient, as in instant claim 39. Thus the ‘494 claims anticipate those of the instant application. Conclusion No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner(s) should be directed to Richard Schnizer, whose telephone number is 571-272-0762. The examiner can normally be reached Monday through Friday between the hours of 6:30 AM and 4:00 PM. The examiner is off on alternate Fridays, but is sometimes in the office anyway. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the Examiner’s supervisor, Ram Shukla, can be reached at 571-272-0735. The official central fax number is 571-273-8300. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to 571-272-0547. For those applications where applicant wishes to communicate with the examiner via Internet communications, e.g., email or video conferencing tools, the following is a sample authorization form which may be used by applicant: "Recognizing that Internet communications are not secure, I hereby authorize the USPTO to communicate with the undersigned and practitioners in accordance with 37 CFR 1.33 and 37 CFR 1.34 concerning any subject matter of this application by video conferencing, instant messaging, or electronic mail. I understand that a copy of these communications will be made of record in the application file." To facilitate processing of the internet communication authorization or withdraw of authorization, the Office strongly encourages use of Form PTO/SB/439, available at www.uspto.gov/patent/patents-forms. The form may be filed via EFS-Web using the document description Internet Communications Authorized or Internet Communications Authorization Withdrawn to facilitate processing. See MPEP 502.03(II). Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /RICHARD A SCHNIZER/Primary Examiner, Art Unit 1635
Read full office action

Prosecution Timeline

Jun 01, 2021
Application Filed
Apr 15, 2025
Non-Final Rejection mailed — §112, §DOUBLEPATENT
Jul 15, 2025
Response Filed
Nov 13, 2026
Final Rejection mailed — §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12774456
Compositions and Methods for Gene Editing
4y 3m to grant Granted Oct 27, 2026
Patent 12774458
BASE EDITING ENZYMES
3y 7m to grant Granted Oct 27, 2026
Patent 12767959
NUCLEOBASE EDITORS HAVING REDUCED OFF-TARGET DEAMINATION AND METHODS OF USING SAME TO MODIFY A NUCLEOBASE TARGET SEQUENCE
5y 2m to grant Granted Oct 20, 2026
Patent 12767939
COMPOSITIONS AND METHODS FOR GENE EDITING
4y 6m to grant Granted Oct 20, 2026
Patent 12752010
PHARMACEUTICAL COMPOSITION CONTAINING ANIONIC DRUG, AND PREPARATION METHOD THEREFOR
4y 9m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
55%
Grant Probability
99%
With Interview (+63.8%)
Moderate
PTA Risk
Based on 56 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month